HONG KONG, Sept. 6, 2011 /PRNewswire-Asia/ — Golden
Meditech Holdings Limited (“Golden Meditech”, together with its
subsidiaries collectively as the “Group”, – 801.HK; 910801.TW),
which embodies a leading medical devices enterprise, a major brand
name in haematology hospital and the largest stem cell cord blood
banking operator in China, is pleased to announce the launch of its
Taiwan representative office today.
With a track record in China for establishing the largest stem
cell cord blood banking corporation, developing a premium hospital
service business, and now, building a cross-straits healthcare
enterprise, Mr. Kam Yuen, Chairman and CEO of Golden Meditech, in
known as a pioneer in China’s healthcare industry. With his
remarkable insights and ability to stay ahead of industry trends
while having the attention and tenacity as an entrepreneur, Mr. Kam
has set his sight on the substantial opportunities in Taiwan’s
medical and bio-tech industries. The Group has already set foot in
Taiwan via issuing Taiwan Depositary Receipts (“TDR”) on the Taiwan
Stock Exchange in January 2011. Mr. Kam is of the view that the
launch of Economic Cooperation Framework Agreement (“ECFA”) and the
policy allowing for easier access between the straits will foster
the development of premium healthcare service sector. Whereas
Taiwan has readily accessible medical expertise and resources, with
the launch of the new Taiwan representative office, the Group will
be able to better leverage its operative advantage, expand its
industry reach and create greater opportunities with its Taiwan
counterpart for greater growth.
Golden Meditech is the first and one the largest blood-related
medical device manufacturers in China with its key product, the
Autologous Blood Recovery System (“ABRS”) accounting for 80% share
of the top-tier hospital market. China’s ongoing medical reform has
created an excellent opportunity for the Group as a pioneer in the
areas of h
‘/>”/>
